Generation of therapeutic antisera for emerging viral infections

npj Vaccines

Volumn 3, Issue 1, 2018, Pages

  Schmidt, Rebecca ^a   Beltzig, Lea C ^a   Sawatsky, Bevan ^a,b   Dolnik, Olga ^b,c   Dietzel, Erik ^b,c   Krähling, Verena ^b,c   Volz, Asisa ^b,d   Sutter, Gerd ^b,d   Becker, Stephan ^b,c   von Messling, Veronika ^a,b  

^a PAUL EHRLICH INSTITUT   (Germany)

^b German Center of Infection Research   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85054548196     PISSN: None     EISSN: 20590105     Source Type: Journal    
DOI: 10.1038/s41541-018-0082-4     Document Type: Article

References (72)

1. Agua-Agum, J. et al. After Ebola in West Africa–unpredictable risks, preventable epidemics. N. Engl. J. Med. 375, 587–596 (2016).
2. Uyeki, T. M. et al. Clinical management of Ebola virus disease in the United States and Europe. N. Engl. J. Med. 374, 636–646 (2016).
3. World Health Organization. Report of an International Commission. Ebola haemorrhagic fever in Zaire, 1976. Bull. World Health Organ. 56, 271–293 (1978).
4. Khan, A. S. et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J. Infect. Dis. 179, S76–S86 (1999).
5. Lo, M. K. et al. Characterization of Nipah virus from outbreaks in Bangladesh, 2008–2010. Emerg. Infect. Dis. 18, 248–255 (2012).
6. Mahalingam, S. et al. Hendra virus: an emerging paramyxovirus in Australia. Lancet Infect. Dis. 12, 799–807 (2012).
7. Paul, L. Nipah virus in Kerala: a deadly zoonosis. Clin. Microbiol. Infect. 10.1016/j.cmi.2018.06.017 (2018).
8. Chua, K. B. et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 354, 1257–1259 (1999).
9. Chua, K. B. et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 288, 1432–1435 (2000).
10. World Health Organization. Statement. Ethical Considerations for Use of Unregistered Interventions for Ebola Virus Disease (EDV): Summary of the Panel Discussion http://www.who.int/mediacentre/news/statements/2014/ebola-ethical-review-summary/en/ (2014).
11. Goh, K. J. et al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N. Engl. J. Med. 342, 1229–1235 (2000).
12. Stille, W. & Böhle, E. in Marburg Virus Disease (eds Martini, G. A. & Siegert, R.) 10–18 (Springer, Berlin, Heidelberg, 1971).
13. Todorovitch, K., Mocitch, M. & Klašnja, R. in Marburg Virus Disease (eds Martini, G. A. & Siegert, R.) 19–23 (Springer, Berlin, Heidelberg, 1971).
14. Mupapa, K. et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J. Infect. Dis. 179, S18–S23 (1999).
15. Jahrling, P. B., Geisbert, J. B., Swearengen, J. R., Larsen, T. & Geisbert, T. W. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 196, S400–S403 (2007).
16. Griensven, J. v. et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl. J. Med. 374, 33–42 (2016).
17. Dye, J. M. et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl. Acad. Sci. USA 109, 5034–5039 (2012).
18. Satterfield, B. A., Dawes, B. E. & Milligan, G. N. Status of vaccine research and development of vaccines for Nipah virus. Vaccine 34, 2971–2975 (2016).
19. Guillaume, V. et al. Nipah virus: vaccination and passive protection studies in a Hamster Model. J. Virol. 78, 834–840 (2004).
20. DeBuysscher, B. L., Scott, D., Marzi, A., Prescott, J. & Feldmann, H. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. Vaccine 32, 2637–2644 (2014).
21. Guillaume, V. et al. Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J. Virol. 80, 1972–1978 (2006).
22. Bossart, K. N. et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection. PLoS Pathog. 5, e1000642 (2009).
23. Center for Disease Control and Prevention. Use of a Reduced (4-Dose) Vaccine Schedule for Postexpousre Prophylaxis to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practice http://www.cdc.gov/mmwr/pdf/rr/rr5902.pdf (2010).
24. Gupta, P. S., Kapoor, R., Goyal, S., Batra, V. K. & Jain, B. K. Intrathecal human tetanus immunoglobulin in early tetanus. Lancet 2, 439–440 (1980).
25. Walsh, J. J. et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin. Infect. Dis. 44, 968–971 (2007).
26. Keller, M. A. & Stiehm, E. R. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13, 602–614 (2000).
27. Boyer, L. et al. Safety of intravenous equine F(ab′)2: insights following clinical trials involving 1534 recipients of scorpion antivenom. Toxicon 76, 386–393 (2013).
28. Jahrling, P. B. et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. Suppl. 11, 135–140 (1996).
29. Zheng, X. et al. Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection. Sci. Rep. 6, 24179 (2016).
30. Noad, R. & Roy, P. Virus-like particles as immunogens. Trends Microbiol. 11, 438–444 (2003).
31. Wahl-Jensen, V. et al. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J. Virol. 79, 2413–2419 (2005).
32. Aleksandrowicz, P. et al. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J. Infect. Dis. 204, S957–S967 (2011).
33. Jasenosky, L. D., Neumann, G., Lukashevich, I. & Kawaoka, Y. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J. Virol. 75, 5205–5214 (2001).
34. Geisbert, T. W. et al. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 4, e1000225 (2008).
35. Marzi, A. et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J. Infect. Dis. 204, S1066–S1074 (2011).
36. Marzi, A. et al. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 349, 739–742 (2015).
37. Krahling, V. et al. Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus. Med. Microbiol. Immunol. 205, 173–183 (2016).
38. Agnandji, S. T. et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N. Engl. J. Med. 374, 1647–1660 (2016).
39. Mire, C. E. et al. Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease. Virol. J. 10, 353 (2013).
40. Walpita, P. et al. A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model. NPJ Vaccin. 2, 21 (2017).
41. Zhu, Z. et al. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J. Virol. 80, 891–899 (2006).
42. Sawatsky, B., Bente, D. A., Czub, M. & Messling, V. v. Morbillivirus and henipavirus attachment protein cytoplasmic domains differently affect protein expression, fusion support and particle assembly. J. Gen. Virol. 97, 1066–1076 (2016).
43. Wang, L.-F. et al. Molecular biology of Hendra and Nipah viruses. Microbes Infect. 3, 279–287 (2001).
44. Silva, H. A. d., Ryan, N. M. & Silva, H. J. d. Adverse reactions to snake antivenom, and their prevention and treatment. Br. J. Clin. Pharmacol. 81, 446–452 (2016).
45. Dart, R. C. & McNally, J. Efficacy, safety, and use of snake antivenoms in the United States. Ann. Emerg. Med. 37, 181–188 (2001).
46. Wong, G. & Kobinger, G. P. Backs against the wall: novel and existing strategies used during the 2014–2015 Ebola virus outbreak. Clin. Microbiol. Rev. 28, 593–601 (2015).
47. Parren, P. W. H. I., Geisbert, T. W., Maruyama, T., Jahrling, P. B. & Burton, D. R. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol. 76, 6408–6412 (2002).
48. Oswald, W. B. et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 3, e9 (2007).
49. Davidson, E. et al. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J. Virol. 89, 10982–10992 (2015).
50. Qiu, X. & Kobinger, G. P. Antibody therapy for Ebola: Is the tide turning around? Hum. Vaccin. Immunother. 10, 964–967 (2014).
51. Kugelman, J. R. et al. Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics. mBio 6, e02227–14 (2015).
52. Dowall, S. D. et al. Development of a cost-effective ovine polyclonal antibody-based product, EBOTAb, to treat Ebola virus infection. J. Infect. Dis. 213, 1124–1133 (2016).
53. Dowall, S. D. et al. Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic. Sci. Rep. 6, 30497 (2016).
54. Dye, J. M. et al. Production of potent fully human polyclonal antibodies against Ebola Zaire virus in transchromosomal cattle. Sci. Rep. 6, 24897 (2016).
55. Schalich, J. et al. Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions. J. Virol. 70, 4549–4557 (1996).
56. Mortola, E. & Roy, P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett. 576, 174–178 (2004).
57. Latham, T. & Galarza, J. M. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol. 75, 6154–6165 (2001).
58. Cervera, L. & Kamen, A. A. Large-scale transient transfection of suspension mammalian cells for VLP production. Methods Mol. Biol. 1674, 117–127 (2018).
59. European Medicines Agency. Production and Quality Control of Animal Immunoglobins and Immunosera for Human Use: EMA/CHMP/BWP/3354/1999. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/08/WC500211639.pdf (2016).
60. Food and Drug Administration. Guidance for Industry. For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Plasma-Derived Biological Products, Animal Plasma or Serum-Derived Products. https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM080825.pdf (1999).
61. Park, G. D. & Mitchel, J. T. Working with the U.S. Food and Drug Administration to obtain approval of products under the Animal Rule. Ann. N. Y. Acad. Sci. 1374, 10–16 (2016).
62. Hofer, M. P. et al. Marketing authorisation of orphan medicines in Europe from 2000 to 2013. Drug Discov. Today 23, 424–433 (2018).
63. Wang, J. W. & Roden, R. B. S. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert. Rev. Vaccin. 12, 129–141 (2013).
64. Boigard, H. et al. Zika virus-like particle (VLP) based vaccine. PLoS Negl. Trop. Dis. 11, e0005608 (2017).
65. Zeltins, A. Construction and characterization of virus-like particles: a review. Mol. Biotechnol. 53, 92–107 (2013).
66. Kushnir, N., Streatfield, S. J. & Yusibov, V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31, 58–83 (2012).
67. Dumont, J., Euwart, D., Mei, B., Estes, S. & Kshirsagar, R. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit. Rev. Biotechnol. 36, 1110–1122 (2016).
68. Clarke, E. C. et al. Production and purification of filovirus glycoproteins in insect and mammalian cell lines. Sci. Rep. 7, 15091 (2017).
69. Kremer, M. et al. Easy and efficient protocols for working with recombinant vaccinia virus MVA. Methods Mol. Biol. 890, 59–92 (2012).
70. Hoenen, T. et al. VP40 octamers are essential for Ebola virus replication. J. Virol. 79, 1898–1905 (2005).
71. Mittler, E., Kolesnikova, L., Hartlieb, B., Davey, R. & Becker, S. The cytoplasmic domain of Marburg virus GP modulates early steps of viral infection. J. Virol. 85, 8188–8196 (2011).
72. Groseth, A. et al. The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog. 8, e1002847 (2012).